Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.0852W HIGH $53,450.61
Volume
8.42 M
Value Traded
21.74 K
Short % Float
99.12%
-72.76%Week
-93.85%1 Month
-99.57%3 Month
-99.92%6 Month
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
89.59 K
EPS (TTM)
-
P/E Ratio
-
Ent. Value
3.60 M
Total Shares
904.47 K
Float Shares
904.47 K
Insiders
0.03%
Institutions
-
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ADTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Aditxt, Inc.
Past FDA Catalysts and PDUFA Decisions
How ADTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D21 / 100
Pipeline Score
$1M
Pipeline Value
Undervalued
Valuation Signal
1
Drugs Scored
7.4x
rNPV / MCap
Aditxt, Inc. faces pipeline headwinds (21/100), with $473M risk-adjusted pipeline value, led by Favipiravir in Covid19 (Phase 3), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Favipiravir Small moleculeCompletedNCT04600895 | Covid19 | Phase 3 | COMPLETED | 1,187 | Oct 20, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every ADTX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Takeover Time 2026 LLC10% Owner | Sell | -3,420,439 | $0.02 | 06/23/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ADTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ADTX for Q2 2026. | ||||
ADTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ADTX ranks across every disease it competes in
Competitive Position is a premium feature
See how ADTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialADTX News
About Aditxt, Inc.
HeadquartersMountain View
Founded2017
BIOPHARMAWATCH ELITE PLUS
Trade the next ADTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime